F Stephen Hodi COSA 2015 ASM

Abstracts this author is presenting:

• Clinical response, progression-free survival (PFS) and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) versus IPI monotherapy in CheckMate 069 study — Best of the Best Posters - Epidemiology & Health services